(NASDAQ: IMTX) Immatics Nv's forecast annual revenue growth rate of -17.03% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 98.52%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.72%.
Immatics Nv's revenue in 2025 is $98,555,813.On average, 13 Wall Street analysts forecast IMTX's revenue for 2025 to be $4,689,324,704, with the lowest IMTX revenue forecast at $3,883,721,209, and the highest IMTX revenue forecast at $5,411,049,156. On average, 13 Wall Street analysts forecast IMTX's revenue for 2026 to be $5,598,500,581, with the lowest IMTX revenue forecast at $1,715,508,755, and the highest IMTX revenue forecast at $10,339,003,656.
In 2027, IMTX is forecast to generate $6,929,502,944 in revenue, with the lowest revenue forecast at $988,800,185 and the highest revenue forecast at $15,036,230,009.